|
1
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, et al:
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yung WK, Prados MD, Yaya-Tur R, et al:
Multicenter phase II trial of temozolomide in patients with
anaplastic astrocytoma or anaplastic oligoastrocytoma at first
relapse. Temodal Brain Tumor Group. J Clin Oncol. 17:2762–2771.
1999.PubMed/NCBI
|
|
4
|
Balmaceda C, Peereboom D, Pannullo S, et
al: Multi-institutional phase II study of temozolomide administered
twice daily in the treatment of recurrent high-grade gliomas.
Cancer. 112:1139–1146. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chamberlain MC and Johnston S: Salvage
chemotherapy with bevacizumab for recurrent alkylator-refractory
anaplastic astrocytoma. J Neurooncol. 91:359–367. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Butowski N, Lamborn KR, Lee BL, et al: A
North American brain tumor consortium phase II study of poly-ICLC
for adult patients with recurrent anaplastic gliomas. J Neurooncol.
91:183–189. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fabrini MG, Silvano G, Lolli I, et al: A
multi-institutional phase II study on second-line Fotemustine
chemotherapy in recurrent glioblastoma. J Neurooncol. 92:79–86.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wen Z, Zhong Z and Darnell JE Jr: Maximal
activation of transcription by Stat1 and Stat3 requires both
tyrosine and serine phosphorylation. Cell. 82:241–250. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu CL, Meyer DJ, Campbell GS, et al:
Enhanced DNA-binding activity of a Stat3-related protein in cells
transformed by the Src oncoprotein. Science. 269:81–83. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Darnell JE Jr, Kerr IM and Stark GR:
Jak-STAT pathways and transcriptional activation in response to
IFNs and other extracellular signaling proteins. Science.
264:1415–1421. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yokogami K, Wakisaka S, Avruch J and
Reeves SA: Serine phosphorylation and maximal activation of STAT3
during CNTF signaling is mediated by the rapamycin target mTOR.
Curr Biol. 10:47–50. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang YW, Wang LM, Jove R and Vande Woude
GF: Requirement of Stat3 signaling for HGF/SF-Met mediated
tumorigenesis. Oncogene. 21:217–226. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu H and Jove R: The STATs of cancer - new
molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bromberg J: Stat proteins and oncogenesis.
J Clin Invest. 109:1139–1142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Darnell JE Jr: STATs and gene regulation.
Science. 277:1630–1635. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Catlett-Falcone R, Landowski TH, Oshiro
MM, et al: Constitutive activation of Stat3 signaling confers
resistance to apoptosis in human U266 myeloma cells. Immunity.
10:105–115. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Duan Z, Foster R, Bell DA, et al: Signal
transducers and activators of transcription 3 pathway activation in
drug-resistant ovarian cancer. Clin Cancer Res. 12:5055–5063. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
D’Atri S, Tentori L, Lacal PM, et al:
Involvement of the mismatch repair system in temozolomide-induced
apoptosis. Mol Pharmacol. 54:334–341. 1998.PubMed/NCBI
|
|
19
|
Margison GP, Povey AC, Kaina B and
Santibanez Koref MF: Variability and regulation of
O6-alkylguanine-DNA alkyltransferase. Carcinogenesis. 24:625–635.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Choi CH: ABC transporters as multidrug
resistance mechanisms and the development of chemosensitizers for
their reversal. Cancer Cell Int. 5:302005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Stavrovskaya AA: Cellular mechanisms of
multidrug resistance of tumor cells. Biochemistry (Mosc).
65:95–106. 2000.PubMed/NCBI
|
|
22
|
Yamauchi T, Ogawa M and Ueda T:
Carmustine-resistant cancer cells are sensitized to temozolomide as
a result of enhanced mismatch repair during the development of
carmustine resistance. Mol Pharmacol. 74:82–91. 2008. View Article : Google Scholar
|
|
23
|
Pegg AE, Dolan ME and Moschel RC:
Structure, function, and inhibition of O6-alkylguanine-DNA
alkyltransferase. Prog Nucleic Acid Res Mol Biol. 51:167–223. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Real PJ, Sierra A, De Juan A, Segovia JC,
Lopez-Vega JM and Fernandez-Luna JL: Resistance to chemotherapy via
Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer
cells. Oncogene. 21:7611–7618. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Duan Z, Ames RY, Ryan M, Hornicek FJ,
Mankin H and Seiden MV: CDDO-Me, a synthetic triterpenoid, inhibits
expression of IL-6 and Stat3 phosphorylation in multi-drug
resistant ovarian cancer cells. Cancer Chemother Pharmacol.
63:681–689. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim JH, Lee SC, Ro J, Kang HS, Kim HS and
Yoon S: Jnk signaling pathway-mediated regulation of Stat3
activation is linked to the development of doxorubicin resistance
in cancer cell lines. Biochem Pharmacol. 79:373–380. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rebbaa A, Chou PM and Mirkin BL: Factors
secreted by human neuroblastoma mediated doxorubicin resistance by
activating STAT3 and inhibiting apoptosis. Mol Med. 7:393–400.
2001.PubMed/NCBI
|
|
28
|
Zhong Z, Wen Z and Darnell JE Jr: Stat3: a
STAT family member activated by tyrosine phosphorylation in
response to epidermal growth factor and interleukin-6. Science.
264:95–98. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wen Z and Darnell JE Jr: Mapping of Stat3
serine phosphorylation to a single residue (727) and evidence that
serine phosphorylation has no influence on DNA binding of Stat1 and
Stat3. Nucleic Acids Res. 25:2062–2067. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kovarik P, Stoiber D, Eyers PA, et al:
Stress-induced phosphorylation of STAT1 at Ser727 requires p38
mitogen-activated protein kinase whereas IFN-gamma uses a different
signaling pathway. Proc Natl Acad Sci USA. 96:13956–13961. 1999.
View Article : Google Scholar
|
|
31
|
Jain N, Zhang T, Kee WH, Li W and Cao X:
Protein kinase C delta associates with and phosphorylates Stat3 in
an interleukin-6-dependent manner. J Biol Chem. 274:24392–24400.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu H, Ma Y, Cole SM, et al: Serine
phosphorylation of STAT3 is essential for Mcl-1 expression and
macrophage survival. Blood. 102:344–352. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hazan-Halevy I, Harris D, Liu Z, et al:
STAT3 is constitutively phosphorylated on serine 727 residues,
binds DNA, and activates transcription in CLL cells. Blood.
115:2852–2863. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Qin HR, Kim HJ, Kim JY, et al: Activation
of signal transducer and activator of transcription 3 through a
phosphomimetic serine 727 promotes prostate tumorigenesis
independent of tyrosine 705 phosphorylation. Cancer Res.
68:7736–7741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi X, Zhang H, Paddon H, Lee G, Cao X and
Pelech S: Phosphorylation of STAT3 serine-727 by cyclin-dependent
kinase 1 is critical for nocodazole-induced mitotic arrest.
Biochemistry. 45:5857–5867. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chung J, Uchida E, Grammer TC and Blenis
J: STAT3 serine phosphorylation by ERK-dependent and -independent
pathways negatively modulates its tyrosine phosphorylation. Mol
Cell Biol. 17:6508–6516. 1997.
|
|
37
|
Yang J, Liao X, Agarwal MK, Barnes L,
Auron PE and Stark GR: Unphosphorylated STAT3 accumulates in
response to IL-6 and activates transcription by binding to
NFkappaB. Genes Dev. 21:1396–1408. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang J, Chatterjee-Kishore M, Staugaitis
SM, et al: Novel roles of unphosphorylated STAT3 in oncogenesis and
transcriptional regulation. Cancer Res. 65:939–947. 2005.PubMed/NCBI
|
|
39
|
Raychaudhuri B, Han Y, Lu T and Vogelbaum
MA: Aberrant constitutive activation of nuclear factor kappaB in
glioblastoma multiforme drives invasive phenotype. J Neurooncol.
85:39–47. 2007. View Article : Google Scholar : PubMed/NCBI
|
